Doxorubicin-Loaded Bi-PEG Nanoparticles as Novel Chemo-Photothermal Nanoagents for Efficiently Killing Cancer Cells
The chemo-photothermal therapy has been proved to be one of efficient strategies for destroying cancer cells, and the prerequisite is to develop photothermal nanoagents with drug-loading capacity. However, most of the current chemo-photothermal nanoagents have multiple structures which require complex synthetic process, undoubtedly hindering their bioapplication. Herein, we prepared PEGylated Bi nanoparticles and loaded with the model drug doxorubicin (DOX), forming [email protected] nanoparticles. Bi-PEG nanoparticles were firstly synthesized through a rapid reduction method and then coated with PEGylated phospholipids, exhibiting strong NIR absorption, high photothermal conversion efficiency of 49.4%, DOX-loading efficiency of 22.8% as well as low cytotoxicity. After incubation with 4T1 cells, [email protected] nanoparticles can be uptaken by cells and then release DOX within cells for chemotherapy. Furthermore, when exposed to 1064 nm laser, these nanoparticles can produce enough heat for photothermal ablating cancer cells. Therefore, the present [email protected] nanoparticles can be served as novel and efficient nanoagents for chemophotothermal therapy of cancer cells.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Affiliations: State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and Engineering, Donghua University, Shanghai 201620, China
Publication date: April 1, 2020
More about this publication?
- Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites